http://www.advfn.com/nasdaq/rss.asp?symbol=ACOR Acorda Therapeutics Company Newsfeed en Mon, 29 Oct 2012 14:50:35 EDT Mon, 29 Oct 2012 14:50:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=54731481&headline=correction-to-2nd-update-on-companies-postponing-earnings-reports http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=54731481&headline=correction-to-2nd-update-on-companies-postponing-earnings-reports <div class='newsbody'><p> "2nd UPDATE: Companies Postpone Earnings Reports in Light of Hurricane Sandy," at 12:04 p.m. EDT, used the incorrect name in the sixth-to-last paragraph for one of the companies that said they intend to report results as planned Tuesday morning. The company is TRW Automotive... Mon, 29 Oct 2012 14:50:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=54724570&headline=companies-postpone-earnings-reports-in-light-of-hurricane-sandy http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=54724570&headline=companies-postpone-earnings-reports-in-light-of-hurricane-sandy <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> A number of U.S. companies disclosed plans to postpone their quarterly reports because of the pending arrival of Hurricane Sandy on the East Coast, a move that comes during one of the busiest weeks of the third-quarter earnings season. </p> <p>... Mon, 29 Oct 2012 08:29:09 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=54373538&headline=petsmart-to-replace-sunoco-in-s-p-500 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=54373538&headline=petsmart-to-replace-sunoco-in-s-p-500 <div class='newsbody'><p> S&amp;P Dow Jones Indices said specialty pet store PetSmart Inc. (PETM) will replace Sunoco Inc. (SUN) in the S&amp;P 500 ahead of an expected acquisition. </p> <p> Independent refiner Sunoco agreed in April to be acquired by Energy Transfer Partners LP (ETP) in a $5.3 billion... Tue, 02 Oct 2012 07:40:13 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=50668473&headline=us-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=50668473&headline=us-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies whose shares are expected to actively trade in Monday's session are Idenix Pharmaceuticals Inc. (IDIX), Inhibitex Inc. (INHX) and GlaxoSmithKline PLC (GSK, GSK.LN). </p> <p> Idenix surged 44% to $10.16 in recent premarket trading in the wake of fellow Hepatitis... Mon, 09 Jan 2012 09:07:39 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=48559587&headline=biogen-acorda-ms-drug-gets-conditional-european-approval http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=48559587&headline=biogen-acorda-ms-drug-gets-conditional-european-approval <div class='newsbody'><p> --Comes after Biogen appealed January rejection </p> <p> --Already approved in U.S. as Ampyra </p> <p> --Acorda, Elan to get payments from approval </p> <pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) received conditional... Mon, 25 Jul 2011 11:44:10 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=48289486&headline=acorda-to-pay-up-to-35-million-to-medtronic-in-licensing-deal http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=48289486&headline=acorda-to-pay-up-to-35-million-to-medtronic-in-licensing-deal <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Acorda Therapeutics Inc. (ACOR) will pay up to $35 million to Medtronic Inc. (MDT) for global development and commercialization rights to the medical-device maker's magnesium formulation as a potential treatment for neurological traumas like spinal... Fri, 01 Jul 2011 08:27:01 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=45977657&headline=biogen-gets-letter-of-deficiency-from-health-canada-on-fampridine http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=45977657&headline=biogen-gets-letter-of-deficiency-from-health-canada-on-fampridine <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) has received a letter of deficiency from Health Canada for its application to sell the multiple sclerosis treatment fampridine in the country. </p> <p> The Weston, Mass., biotech... Tue, 11 Jan 2011 20:23:15 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=45830933&headline=approvals-of-new-drugs-down-in-2010-vs-2009-2008 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=45830933&headline=approvals-of-new-drugs-down-in-2010-vs-2009-2008 <div class='newsbody'><p> By Jennifer Corbett Dooren </p> <p> Of DOW JONES NEWSWIRES </p> <p> WASHINGTON -(Dow Jones)- The number of new drugs approved by the Food and Drug Administration in 2010 looks to be about 21, a relatively low figure that shows the pharmaceutical industry hasn't yet escaped its... Thu, 30 Dec 2010 17:22:24 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=45588663&headline=biogen-ceo-expects-to-make-biotech-generics-as-market-develops http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=45588663&headline=biogen-ceo-expects-to-make-biotech-generics-as-market-develops <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) is likely to produce generic versions of biologic drugs as that niche industry develops and patents expire, marking a new foray for the biotech company, Chief Executive George... Thu, 09 Dec 2010 11:07:09 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=44757511&headline=acorda-ms-drug-to-get-improved-reimbursement-from-unitedhealth http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=44757511&headline=acorda-ms-drug-to-get-improved-reimbursement-from-unitedhealth <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- UnitedHealth Group Inc. (UNH) plans to increase the reimbursement status of Acorda Therapeutics Inc.'s (ACOR) multiple sclerosis drug Ampyra, a positive development in an area that has been a concern... Tue, 12 Oct 2010 15:20:08 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=43884183&headline=correct-acorda-shares-up-as-ms-drug-ampyra-shows-early-strength http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=43884183&headline=correct-acorda-shares-up-as-ms-drug-ampyra-shows-early-strength <div class='newsbody'><p> ("=CORRECT: Acorda Shares Up As MS Drug Ampyra Shows Early Strength In 2Q," at 12:56 p.m. EDT Tuesday, incorrectly reported the company's cash, cash equivalents and short-term investments. A correct version follows) </p> <pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p>... Wed, 04 Aug 2010 17:55:05 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=43860453&headline=acorda-shares-up-as-ms-drug-ampyra-shows-early-strength-in-2q http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=43860453&headline=acorda-shares-up-as-ms-drug-ampyra-shows-early-strength-in-2q <div class='newsbody'><pre> By Thomas Gryta Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Acorda Therapeutics Inc. (ACOR) reported strong sales in its first full quarter of selling the multiple sclerosis symptoms treatment Ampyra, sending its shares 6.3% higher in midday trading. </p> <p>... Tue, 03 Aug 2010 13:26:06 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=41229034&headline=fda-oks-ampyra-to-improve-walking-in-adults-with-multiple-sclerosis http://www.advfn.com/nasdaq/StockNews.asp?stocknews=ACOR&article=41229034&headline=fda-oks-ampyra-to-improve-walking-in-adults-with-multiple-sclerosis <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Friday approved a new drug from Acorda Therapeutics Inc. (ACOR) to improve walking in patients with multiple sclerosis. </p> <p> The FDA said the drug... Fri, 22 Jan 2010 16:28:14 EST